Rockefeller Capital Management
ITCI

Rockefeller Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Rockefeller Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,085
Closed -$275K – 2050
2023
Q1 		$275K Buy
5,085
+1,519
+43% +$73.4K ﹤0.01% 1632
2022
Q4 		$188K Buy
3,566
+74
+2% +$3.71K ﹤0.01% 1695
2022
Q3 		$162K Buy
3,492
+3,274
+1,502% +$171K ﹤0.01% 1745
2022
Q2 		$12K Buy
218
+192
+738% +$10.9K ﹤0.01% 3039
2022
Q1 		$1K Buy
+26
New +$1.35K ﹤0.01% 3800

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's ITCI Position: Q2 2023 in Review

Rockefeller Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 5,085 shares — an estimated $275K sold.

Rockefeller Capital Management first reported a position in ITCI in Q1 2022 and held it in 5 quarters. The position peaked at $275K in Q1 2023. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Rockefeller Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 5,085 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $275K.
  • Rockefeller Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 5 quarters.
  • Rockefeller Capital Management's Intra-Cellular Therapies Inc. position peaked at $275K in Q1 2023.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Rockefeller Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.